FDA Approves Zelboraf (Vemurafenib) for Metastatic Melanoma

FDA Approves Zelboraf (Vemurafenib) for Metastatic Melanoma

The drug is specifically indicated for patients with melanoma whose tumors have V600E mutations in theBRAF gene. An estimated 50% of patients with melanoma have this type of BRAF mutation, which does not occur in normal cells. The drug is not indicated for use in patients without the mutation.......